PAVmed Inc. (NasdaqCM:PAVM) entered into a definitive membership interests purchase agreement to acquire CapNostics, LLC from Martin Von Dyck for approximately $2.1 million on October 5, 2021. Concurrently, the PAVmed entered into an exclusive long-term consulting agreement with Von Dyck, as well as an exclusive long-term manufacturing agreement with the EsophaCap contract manufacturer. Ascendiant capital markets, LLC acted as an advisor to the transaction.

PAVmed Inc. (NasdaqCM:PAVM) completed the acquisition of CapNostics, LLC from Martin Von Dyck on October 5, 2021. The consideration is payable in cash. Ascendiant Capital Markets LLC acted as a financial advisor to PAVmed Inc.